AlveoGene

AlveoGene is a new gene therapy company co-founded and funded by OSE, Harrington, and OCC in collaboration with six leading scientists from the world-renowned British Respiratory Gene Therapy Consortium (GTC). AlveoGene has obtained an exclusive license for the next-generation lentiviral delivery platform developed by GTC, which is proprietary and proven for use in treating respiratory diseases with unmet therapeutic needs (excluding the use of the CFTR gene for cystic fibrosis variants).